<DOC>
	<DOCNO>NCT01430013</DOCNO>
	<brief_summary>To evaluate efficacy safety Endostar combine CHOPT treatment T cell lymphoma .</brief_summary>
	<brief_title>Trial Endostar Combined With CHOPT T Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<criteria>1 . Male female age 18 70 year old . 2 . Diagnosis T cell lymphoma accord WHO Classification , without antitumor therapy 3 . At least 1 measurable tumor mass ( great 1.5cm long dimension great 1.0 short axis ) 4 . Eastern Cooperative Oncology Group status 02 5 . White blood cell≥4.0×109cells/L ; Absolute neutrophil count ( ANC ) ≥1.5×109cells /L ; Platelets≥100×109cells/L 6 . Alanine transaminase ( ALT ) ≤2×upper limit normal ( ULN ) ; Aspartate transaminase ( AST ) ≤2×ULN ; Total Bilirubin≤1.5×ULN ; Creatinine normal range 1 . No active central nervous system lymphoma brain tumor 2 . Suppurative inflammation , Chronic infection 3 . Severe heart disease , conclusion : congestive heart failure ; uncontrolled cardiac arrhythmia ; myocardial infarction ; refractory hypertension 4. psychiatric history 5 . Primary cutaneous T cell lymphoma 6 . Pregnant lactate woman 7 . Concurrent treatment another investigational agent 8 . Accept radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>